Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
In the citing paper
“Clearly, molecular weight is a physicochemical parameter fundamental for CNS penetration and for the overall profile of drugs against neurodegenerative diseases.103,104”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Self-citationPhysiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Self-citationCNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Self-citationGhose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Development of a new permeability assay using low‐efflux MDCKII cells
Di, L., Whitney‐Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22674 · Cited by 313
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Ertl, P. (2007) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621286.ch5 · Cited by 75
Research works printed but not linked: 1
- Harrington, E. C., Jr. (1965) The desirability function. Indust. Qual. Control 21, 494-498.
Cited by
Items 201–300 of 746
Novel SK channel positive modulators prevent ferroptosis and excitotoxicity in neuronal cells
Zhang, Y., Shaabani, S., Vowinkel, K., Trombetta-Lima, M., Sabogal-Guáqueta, A. M., Chen, T., Hoekstra, J., Lembeck, J., Schmidt, M., Decher, N., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116163 · Cited by 18
“Especially to mention is the highly promising blood brain barrier penetration prediction, while having a low molecular weight (e. g. C6: CNS MPO 4.52; 332 Dalton) [56].”
InfluentialMarinho, M. M., da Rocha, M. N., Magalhães, E. P., Ribeiro, L. R., Roberto, C. H. A., Almeida-Neto, F. W. Q., Monteiro, M. L., Nunes, J. V. S., de Menezes, R. R. P. P. B., Marinho, E. S., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03138-z · Cited by 18
“…the human liver microsome (CL HLM < 100 mL/min/kg) are concentrated, formed by compounds with − 2 < logD at pH 7.4 ≤ 5 (within the range of MW ≤ 500 g/mol), that is, with physicochemical balance between solubility and permeability (Johnson et al. 2009; Wager et al. 2016; Petters-son et al. 2016).”
InfluentialDantas, D. D. M., Macêdo, N. S., Silveira, Z. D. S., Barbosa, C. R. D. S., Muniz, D. F., Bezerra, A. H., de Sousa, J. T., Alencar, G. G., Oliveira–Tintino, C. D. D. M., Tintino, S. R., et al. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107504 · Cited by 18
Davis, A. M., & Leeson, P. D. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00001 · Cited by 18
Valipour, M., Mohammadi, M., & Valipour, H. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03829-3 · Cited by 17
“The importance of appropriateness of these physicochemical parameters for drugs intended to act in the CNS is crucial [38].”
Xavier, M. R., Marinho, M. M., Julião, M. S. D. S., Marinho, E. S., Almeida-Neto, F. W. Q., de Castro, K. K. A., da Hora, J. P., da Rocha, M. N., Barreto, A. C. H., Saraiva, G. D., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138019 · Cited by 17
Lopes, F. F. D. S., Lúcio, F. N. M., da Rocha, M. N., de Oliveira, V. M., Roberto, C. H. A., Marinho, M. M., Marinho, E. S., & de Morais, S. M. (2024) · 3 Biotech · doi:10.1007/s13205-024-03978-9 · Cited by 17
“According to Wager et al. (2016), compounds that have low lipophilicity (logP < 3) and high topological polarity (TPSA > 75) are associated with high cell viability and greater safety to the CNS (Hughes et al. 2008).”
Cook, B. E., Pickel, T. C., Nag, S., Bolduc, P. N., Beshr, R., Forsberg, A., Muste, C. A., Boscutti, G., Jiang, D. M., Yuan, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adl1732 · Cited by 17
Margaryan, T., Elliott, M., Sanai, N., & Tovmasyan, A. G. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.05.003 · Cited by 17
Fortin, J. S., Shimanaka, K., Saraswati, A. P., Liu, M., Wang, K., Hagar, H. C., Maity, S., Ganegamage, S. K., Ellsworth, E. L., Counts, S., et al. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133574 · Cited by 17
Liang, Z., & Maher, P. A. (2022) · Antioxidants · doi:10.3390/antiox11112197 · Cited by 17
“The desired properties of central nervous system (CNS) druglikeness were evaluated on the basis of the previously published methods [14,15].”
MethodThe discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core
Bertron, J. L., Cho, H. P., García-Barrantes, P. M., Panarese, J. D., Salovich, J. M., Nance, K. D., Engers, D. W., Rook, J. M., Blobaum, A. L., Niswender, C. M., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.009 · Cited by 17
Smelt, C. L. C., Sanders, V. R., Newcombe, J., Burt, R. P., Sheppard, T. D., Topf, M., & Millar, N. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.07.009 · Cited by 17
PET Imaging of Innate Immune Activation Using 11 C Radiotracers Targeting GPR84
Kalita, M., Park, J. H., Kuo, R., Hayee, S., Marsango, S., Straniero, V., Alam, I. S., Rivera‐Rodriguez, A., Pandrala, M., Carlson, M. L., et al. (2023) · JACS Au · doi:10.1021/jacsau.3c00435 · Cited by 16
“12 Additionally, in a mouse model of partial sciatic nerve ligation, gpr84 mRNA expression in peripheral macrophages was upregulated in the sciatic nerve and spinal cord on days 7 and 21 while g pr84 knockout mice displayed reduced neuropathic pain.”
BackgroundSantambrogio, A., Horne, R. I., Metrick, M. A., Gallagher, N. C. T., Brotzakis, Z. F., Rinauro, D. J., Vourkou, E., Papanikolopoulou, K., Skoulakis, E. M. C., Linse, S. S., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c12812 · Cited by 17
“Promising candidate compounds were demonstrated to specifically inhibit both secondary aggregation processes as well as elongation in polymorph-specific aggregation assays.”
Tufi, R., Clark, E. H., Hoshikawa, T., Tsagkaraki, C., Stanley, J., Takeda, K., Staddon, J. M., & Briston, T. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.12.004 · Cited by 16
Current Small Molecule–Based Medicinal Chemistry Approaches for Neurodegeneration Therapeutics
Sanghai, N., Vuong, B., Berk, A. B., Afridi, M. S. K., & Tranmer, G. K. (2024) · ChemMedChem · doi:10.1002/cmdc.202300705 · Cited by 16
Bender, A. M., Cho, H. P., Nance, K. D., Lingenfelter, K. S., Luscombe, V. B., Gentry, P. R., Voigtritter, K. R., Berizzi, A. E., Sexton, P. M., Langmead, C. J., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00126 · Cited by 16
Strategies for targeting the P2Y12 receptor in the central nervous system
Ben, B., Montgomery, A. P., Chen, B., Kassiou, M., & Danon, J. J. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128837 · Cited by 15
Interactive Python Notebook Modules for Chemoinformatics in Medicinal Chemistry
Mahjour, B. A., McGrath, A., Outlaw, A., Zhao, R., Zhang, C., & Cernak, T. (2023) · Journal of Chemical Education · doi:10.1021/acs.jchemed.3c00357 · Cited by 15
Horne, R. I., Wilson-Godber, J., Díaz, A. G., Brotzakis, Z. F., Seal, S., Gregory, R. C., Possenti, A., Chia, S., & Vendruscolo, M. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01777 · Cited by 15
Sun, D., Macedonia, C. R., Chen, Z., Chandrasekaran, S., Najarian, K., Zhou, S. Y., Cernak, T., Ellingrod, V. L., Jagadish, H. V., Marini, B. L., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01684 · Cited by 15
Using Bibliometric Analysis and Machine Learning to Identify Compounds Binding to Sialidase-1
Klein, J. J., Baker, N., Foil, D. H., Zorn, K. M., Urbina, F., Puhl, A. C., & Ekins, S. (2021) · ACS Omega · doi:10.1021/acsomega.0c05591 · Cited by 15
Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma
Wang, Q.-X., Zhang, P.-Y., Li, Q., Tong, Z., Wu, J.-Z., Yu, S., Yu, Y., Ding, N., Leng, X.-J., Chang, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115464 · Cited by 15
Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels
Sairaman, A., Cardoso, F. C., Bispat, A. S., Lewis, R. J., Duggan, P. J., & Tuck, K. L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.031 · Cited by 15
Lambert, L. J., Grotegut, S., Celeridad, M., Gosalia, P., Backer, L. J. S. D., Bobkov, A. A., Salaniwal, S., Chung, T. D. Y., Zeng, F., Pass, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094417 · Cited by 15
“Our selection was based on the central nervous system (CNS) multiparameter optimization (MPO) score [50,51], which predicts the potential of compounds to penetrate the brain.”
MethodBoudreau, M. W., Mulligan, M. P., Shapiro, D. J., Fan, T. M., & Hergenrother, P. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01730 · Cited by 15
Stalińska, J., Vittori, C., Ingraham, C. H., IV, Carson, S. C., Plaisance‐Bonstaff, K., Lassak, A., Faia, C., Colley, S. B., Peruzzi, F., Reiss, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07247-8 · Cited by 15
da Rocha, M. N., Marinho, M. M., dos Santos, H. S., Marinho, E. S., Ildefonso, J., Rosas, J. F., & Coutinho, H. D. M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136508 · Cited by 14
Barbosa, C. R. D. S., Macêdo, N. S., Silveira, Z. D. S., Rocha, J. E., de Freitas, T. S., Muniz, D. F., Araújo, I. M., Oliveira–Tintino, C. D. D. M., Marinho, E. S., da Rocha, M. N., et al. (2023) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2023.109782 · Cited by 14
Discovery of novel indole derivatives as potent and selective inhibitors of proMMP-9 activation
Nishikawa‐Shimono, R., Kuwabara, M., Fujisaki, S., Matsuda, D., Endo, M., Kamitani, M., Futamura, A., Nomura, Y., Yamaguchi-Sasaki, T., Yabuuchi, T., et al. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129541 · Cited by 14
The development of a PET radiotracer for imaging alpha synuclein aggregates in Parkinson's disease
Tian, G., Hsieh, C., Guarino, D. S., Graham, T. J. A., Lengyel‐Zhand, Z., Schmitz, A. M. T., Chia, W., Young, A. J., Crosby, J.-G., Plakas, K., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00057b · Cited by 14
The Logic of Chemical Optimization
Kombo, D. C., & LaMarche, M. J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00445 · Cited by 14
Applications of artificial intelligence in drug discovery for neurological diseases
Ekins, S., & Lane, T. R. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00624 · Cited by 14
“Another example tested an updated method on 21 CNS candidates with 77 % correct [199].”
Hamed, R., Eyal, A. D., Berman, E., & Eyal, S. (2022) · Epilepsia · doi:10.1111/epi.17479 · Cited by 14
Ma, H., Pagare, P. P., Li, M., Neel, L. T., Mendez, R. E., Gillespie, J. C., Stevens, D. L., Dewey, W. L., Selley, D. E., & Zhang, Y. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01499 · Cited by 14
Ferreira, M. K. A., Freitas, W. P. O., Barbosa, I. M., da Rocha, M. N., da Silva, A. W., Rebouças, E. D. L., Mendes, F. R. D. S., Alves, C. R., Nunes, P. I. G., Marinho, M. M., et al. (2023) · 3 Biotech · doi:10.1007/s13205-023-03696-8 · Cited by 14
Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder
Boateng, C. A., Nilson, A. N., Placide, R., Pham, M. L., Jakobs, F. M., Boldizsar, N. M., McIntosh, S., Stallings, L. S., Korankyi, I. V., Kelshikar, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00734 · Cited by 14
“8, respectively shown in Supplemental Table S3; scores >4 correlate with CNS drug-like properties.(23) 5f was also tested in Caco-2 membrane permeability assays (Eurofins Panlabs, St.”
BackgroundAminotriazines with indole motif as novel, 5-HT7 receptor ligands with atypical binding mode
Kułaga, D., Jaśkowska, J., Satała, G., Latacz, G., & Śliwa, P. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104254 · Cited by 14
Roecker, A. J., Layton, M. E., Pero, J. E., Kelly, M. J., Greshock, T. J., Kraus, R. L., Li, Y., Klein, R. M., Clements, M. K., Daley, C., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00218 · Cited by 14
Eivazzadeh‐Keihan, R., Dogari, H., Ahmadpour, F., Aliabadi, H. A. M., Radinekiyan, F., Maleki, A. R., Fard, L. S., Tahmasebi, B., Mojdehi, M. F., & Mahdavi, M. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-92919-0 · Cited by 14
Wong, D. R., Conrad, J. C., Johnson, N. R., Ayers, J. I., Laeremans, A., Lee, J. C., Lee, J., Prusiner, S. B., Bandyopadhyay, S., Butte, A. J., et al. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-022-00490-8 · Cited by 14
“The screened compound collection is from the Chembridge Central Nervous System (CNS) library with a multiple parameter optimization score greater than four 55,56 .”
Zampieri, D., Fortuna, S., Calabretti, A., Romano, M., Menegazzi, R., Schepmann, D., Wünsch, B., Collina, S., Zanon, D., & Mamolo, M. G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.012 · Cited by 14
Rosenthal, Z. C., Fass, D. M., Payne, N. C., She, A., Patnaik, D., Hennig, K. M., Tesla, R., Werthmann, G. C., Guhl, C., Reis, S. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59110-7 · Cited by 13
“To guide our synthetic efforts, we utilized CNS Multiparameter Optimization (MPO) scoring, which has previously been used to guide the optimization of drug candidates for desirable ADME attributes, safety profiles, and CNS permeability 73,74 .”
MethodGiorgioni, G., Bonifazi, A., Botticelli, L., Cifani, C., Matteucci, F., Bonaventura, E. M. D., Bonaventura, M. V. M. D., Giannella, M., Piergentili, A., Piergentili, A., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22049 · Cited by 13
What Happens in Successful Optimizations? A Survey of 2018–2024 Literature
Leeson, P. D. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03171 · Cited by 13
de Souza, M. A., de Castro, K. K. A., Almeida-Neto, F. W. Q., Bandeira, P. N., Ferreira, M. K. A., Marinho, M. M., da Rocha, M. N., de Brito, D. H. A., Mendes, F. R. D. S., Rodrigues, T. H. S., et al. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.132064 · Cited by 13
Advances in prodrug design for Alzheimer’s disease: the state of the art
Travers--Lesage, V., Mignani, S. M., Dallemagne, P., & Rochais, C. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2031972 · Cited by 13
“A multiparameter optimization desirability process was highlighted for CNS drugs leading to CNS drug property space [17].”
MethodHuang, B., Li, M., Klongkumnuankarn, P., Mendez, R. E., Gillespie, J. C., Stevens, D. L., Dewey, W. L., Selley, D. E., & Zhang, Y. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02185 · Cited by 13
Kaide, S., Watanabe, H., Iikuni, S., Hasegawa, M., & Ono, M. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00473 · Cited by 13
Shi, D., Chahal, K. K., Oto, P., Nothias-Scaglia, L.-F., Debnath, A., McKerrow, J. H., Podust, L. M., & Abagyan, R. A. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00227 · Cited by 13
Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist
Long, D. D., Armstrong, S. R., Beattie, D. T., Campbell, C. B., Church, T. J., Colson, P.-J., Dalziel, S. M., Jacobsen, J. R., Jiang, L., Obedencio, G. P., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00406 · Cited by 13
Grandjean, J.-M. M., Jiu, A. Y., West, J. W., Aoyagi, A., Droege, D. G., Elepano, M., Hirasawa, M., Hirouchi, M., Murakami, R., Lee, J., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00480 · Cited by 13
Discovery of CVN636 : A Highly Potent, Selective, and CNS Penetrant mGluR 7 Allosteric Agonist
Dickson, L., Teall, M. R., Chevalier, E., Cheung, T., Liwicki, G. M., Mack, S. R., Stephenson, A., White, K., Fosbeary, R., Harrison, D. C., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00529 · Cited by 13
Bewley, B. R., Spearing, P. K., Weiner, R. L., Luscombe, V. B., Zhan, X., Chang, S., Cho, H. P., Rodriguez, A. L., Niswender, C. M., Conn, P. J., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.043 · Cited by 13
Lima, J. P. O., da Fonseca, A. M., Marinho, G. S., da Rocha, M. N., Marinho, E. M., dos Santos, H. S., Freire, R. M., Marinho, E. S., de Lima‐Neto, P., & Fechine, P. B. A. (2023) · 3 Biotech · doi:10.1007/s13205-023-03695-9 · Cited by 12
Ebselen analogues delay disease onset and its course in fALS by on-target SOD-1 engagement
Watanabe, S., Amporndanai, K., Awais, R., Latham, C., Awais, M., O’Neill, P. M., Yamanaka, K., & Hasnain, S. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-62903-5 · Cited by 12
“These compounds were designed to penetrate the blood–brain barrier by use of the Pfizer multiparameter optimisation (MPO) approach to CNS drug design 25,28 .”
MethodBaşar, Y., Yenigün, S., Özen, T., Demirtaş, İ., Balpınar, Ö., & Behçet, L. (2025) · European Food Research and Technology · doi:10.1007/s00217-025-04831-w · Cited by 12
Hashimoto, K., Ide, S., Arata, M., Nakata, A., Ito, A., Ito, T. K., Kudo, N., Lin, B., Nunomura, K., Tsuganezawa, K., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00081 · Cited by 12
Pasieka, A., Panek, D., Zaręba, P., Sługocka, E., Gucwa, N., Espargaró, A., Latacz, G., Khan, N., Bucki, A., Sabaté, R., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117333 · Cited by 12
Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET
Schlein, E., Rokka, J., Odell, L. R., van den Broek, S. L., Herth, M. M., Battisti, U. M., Syvänen, S., Sehlin, D., & Eriksson, J. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00250-6 · Cited by 12
Medicines discovery for auditory disorders: Challenges for industry
Cousins, R. P. C. (2019) · The Journal of the Acoustical Society of America · doi:10.1121/1.5132706 · Cited by 12
Bucki, A., Marcinkowska, M., Śniecikowska, J., Zagórska, A., Jamrozik, M., Pawłowski, M., Głuch‐Lutwin, M., Siwek, A., Jakubczyk, M., Pytka, K., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112149 · Cited by 12
Heitmann, T., Liao, G., Ernst, G. E., Poslusney, M. S., van Kralingen, T., Li, Y., Masi, M., Depasquale, M. J., Buchler, I. P., Wei, H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00190 · Cited by 11
Bateman, T. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00019-7 · Cited by 11
Modemann, D. J., Mahardhika, A. B., Yamoune, S., Kreyenschmidt, A.-K., Maaß, F., Kremers, S., Breunig, C., Sahlmann, C., Bucerius, J. A., Stalke, D., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114138 · Cited by 11
Oliveira, L. S., Ferreira, M. K. A., Almeida-Neto, F. W. Q., da Silva, A. W., Filho, J. I. L. P., da Rocha, M. N., Marinho, E. M., Ribeiro, W. H. F., Marinho, M. M., Marinho, E. S., et al. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12960 · Cited by 11
“A CNS MPO score ≥ 4 indicates good pharmacokinetic alignment [74].”
BackgroundDevelopment of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas
Warda, A., Staniszewski, L. J. P., Sabir, Z. L., Livingston, S., Sausedo, M. A., Reshi, S. M., Ron, E. S., Applegate, M. T., Haddad, D., Khamisi, M., et al. (2023) · Cells · doi:10.3390/cells12212575 · Cited by 11
Bolduc, P. N., Pfaffenbach, M., Evans, R., Xin, Z., Henry, K. L., Gao, F., Fang, T., Silbereis, J. C., Rebollar, J. V., Li, P., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00102 · Cited by 11
Belarmino, A. B., de Sousa, D. S., Roberto, C. H. A., de Oliveira, V. M., da Rocha, M. N., Mendes, F. R. D. S., Marinho, M. M., da Fonseca, A. M., & Marinho, G. S. (2024) · Steroids · doi:10.1016/j.steroids.2024.109453 · Cited by 11
El‐Shorbagi, A., & Chaudhary, S. (2019) · Letters in Drug Design & Discovery · doi:10.2174/1570180816666190516113202 · Cited by 11
Porter, J. D., Vivas, O., Weaver, C. D., Alsafran, A., DiMilo, E., Arnold, L. A., Dickson, E. J., & Dockendorff, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126681 · Cited by 11
A Pentacyclic Triterpene from Ligustrum lucidum Targets γ-Secretase
Luo, W., Ip, F. C. F., Fu, G., Cheung, K., Tian, Y., Hu, Y., Sinha, A., Cheng, E. Y. L., Wu, X., Bustos, V., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00389 · Cited by 11
Kirk, R. D., Picard, K. L., Christian, J. A., Johnson, S. L., DeBoef, B., & Bertin, M. J. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00686 · Cited by 11
Murrell, E., Tong, J., Smil, D. V., Kiyota, T., Aman, A. M., Isaac, M. B., Watson, I. D. G., & Vasdev, N. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00127 · Cited by 11
Janssens, L. K., Ametovski, A., Sparkes, E., Boyd, R. A., Lai, F., Maloney, C. J., Rhook, D., Gerona, R. R. L., Connolly, M., Liu, H., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00408 · Cited by 11
Visualizing GABA transporters in vivo: an overview of reported radioligands and future directions
Knippenberg, N., Bauwens, M., Schijns, O. E. M. G., Hoogland, G., Florea, A., Rijkers, K., Cleij, T. J., Eersels, K., van Grinsven, B., & Diliën, H. (2023) · EJNMMI Research · doi:10.1186/s13550-023-00992-5 · Cited by 11
Felts, A. S., Bollinger, K. A., Brassard, C. J., Rodriguez, A. L., Morrison, R. D., Daniels, J. S., Blobaum, A. L., Niswender, C. M., Jones, C. K., Conn, P. J., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.017 · Cited by 11
Ghashghaei, O., Kielland, N., Revés, M., Taylor, M. C., Kelly, J. M., Pietro, O. D., Muñoz‐Torrero, D., Pérez, B., & Lavilla, R. (2018) · Molecules · doi:10.3390/molecules23010177 · Cited by 11
“Of note, researchers from Pfizer recently disclosed an in silico method for the evaluation of the likeliness of a given compound to act in the CNS [19], which is based on the calculation of the so-called CNS multiparameter optimization (CNS MPO) algorithm [20,21].”
MethodEradication of ENO1 -deleted Glioblastoma through Collateral LethalityPreprint
Lin, Y.-H., Satani, N., Hammoudi, N., Ackroyd, J. J., Khadka, S., Yan, V. C., Georgiou, D. K., Sun, Y., Zielinski, R. J., Tran, T. T., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/331538 · Cited by 11
Eneberg, E., Jones, C. R., Jensen, T. N., Langthaler, K., & Bundgaard, C. (2022) · Drug Metabolism and Bioanalysis Letters · doi:10.2174/1872312815666220222091032 · Cited by 10
Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer’s Disease
Warren, H. T., Saeger, H. N., Tombari, R. J., Chytil, M., Rasmussen, K., & Olson, D. E. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01696 · Cited by 10
Central nervous system distributional kinetics of selected histone deacetylase inhibitors
Zhang, W., Oh, J., Zhang, W., Aldrich, C. C., Sirianni, R. W., & Elmquist, W. F. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002170 · Cited by 10
Charnelle, E., Gobert, A., Marteau, R., Pautric, M., Renault, N., Jonneaux, A., Dorooee, D. M., Laversin, A., Devedjian, J.-C., Melnyk, P., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00739 · Cited by 10
Marotta, G., Massenzio, F., Ortega, J., Russo, D., Penna, I., Falchi, F., Babini, G., Petralla, S., Scarpelli, R., Roggiolani, E., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00629 · Cited by 10
Tiwari, S., Mądra-Gackowska, K., Gackowski, M., Park, N., & Szeleszczuk, Ł. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060670 · Cited by 10
“Early QSPR models employed linear regression with lipophilicity, molecular weight, and polar surface area descriptors, establishing foundational rules including the CNS Multiparameter Optimisation (MPO) scoring function [15,16].”
Evolutionary Multi-objective Design of SARS-CoV-2 Protease Inhibitor Candidates
Cofala, T., Elend, L., Mirbach, P., Prellberg, J., Teusch, T., & Kramer, O. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-58115-2_25 · Cited by 10
Long, M. F., Capstick, R. A., Spearing, P. K., Engers, J. L., Gregro, A. R., Bollinger, S. R., Chang, S., Luscombe, V. B., Rodriguez, A. L., Cho, H. P., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128416 · Cited by 10
de Menezes, J. F. S., Silva, A. M. S. P., de Almeida, E. A. F., da Silva, A. F., Lima, J. M. B. D., da Silva, A. W., Ferreira, M. K. A., de Menezes, J. E. S. A., dos Santos, H. S., Marinho, E. S., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2199087 · Cited by 10
“This empirical decision corroborates the estimated pharmacokinetic descriptors since the P app MDCK coefficient on the order of 1.84 � 10 (cid:0) 9 cm/s (Optimal: P app 10 � 10 (cid:0) 5 cm/s) indicates a low passive intestinal permeability (Wager et al., 2016).”
BackgroundInfluentialNitroaromatic-based triazene prodrugs to target the hypoxic microenvironment in glioblastoma
Braga, C., Ferreira-Silva, M., Corvo, M. L., Moreira, R., Fernandes, A. R., Vaz, J., & Perry, M. D. J. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00876f · Cited by 10
Silveira, Z. D. S., Macêdo, N. S., Dantas, D. D. M., Barbosa, C. R. D. S., Muniz, D. F., Oliveira–Tintino, C. D. D. M., Tintino, S. R., Alencar, G. G., Marinho, E. S., da Rocha, M. N., et al. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107318 · Cited by 10
The neuronal calcium ion channel activity of constrained analogues of MONIRO-1
Cardoso, F. C., Marliac, M.-A., Geoffroy, C., Schmit, M., Bispat, A. S., Lewis, R. J., Tuck, K. L., & Duggan, P. J. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115655 · Cited by 10
Shi, J., Jiang, Q.-H., Zhang, T.-N., Sun, H., Shi, W., Gunosewoyo, H., Yang, F., Tang, J., Pang, T., & Yu, L.-F. (2021) · Molecules · doi:10.3390/molecules26051212 · Cited by 10
“Compound Tested Pe 10−6 cm/s a Theoretical Pe 10−6 cm/s LogBB b CNS MPO c Verapamil 12.3 ± 0.41 16.0 / / Atenolol 0.81 ± 0.22 0.8 / / TS-157 3.15 ± 0.35 −0.005 5.4 a See Experimental Section.”
MethodInfluentialFrota, L. S., da Rocha, M. N., Bezerra, L. L., da Fonseca, A. M., Marinho, E. S., & de Morais, S. M. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2112619 · Cited by 10
“2 D structure of (A) Amentoflavone (C30H18O10) and (B) Agathisflavone (C30H18O10). cell membranes within the Pfizer classification system (Papp 10 10 6 cm/s) (Wager et al., 2016), with a low risk of efflux by P-gp, favorable to the antiproliferative effect of biflavonoids in cancerous cells.”
BackgroundKashyap, K., Panigrahi, L., Ahmed, S., & Siddiqi, M. I. (2023) · Molecular Informatics · doi:10.1002/minf.202200113 · Cited by 10
de Souza, M. A., Rodrigues, L. G., Rocha, J. E., de Freitas, T. S., Bandeira, P. N., Marinho, M. M., da Rocha, M. N., Marinho, E. S., Barreto, A. C. H., Coutinho, H. D. M., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2213777 · Cited by 10
“…90, HBD 1 and pKa � 8) of the Central Nervous System Multiparameter Optimization (CNS MPO) algorithm from the pharmaceutical company Pfizer, Inc. (Wager et al., 2016),, where values greater than 4.0 present a good alignment of the pharmacokinetic attributes: high passive permeability (Papp), low…”
InfluentialAjayi, E. D., Elazazy, M., Abouzid, K. A. M., & Ali, H. I. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118219 · Cited by 9
Pharmacologic inhibition of PCBP2 biomolecular condensates relieves Alzheimer’s disease
Wang, L., Xie, X., Pan, Q., Zhang, J., Zhou, G., Zhang, Q., Yan, X., Xiang, Y., Li, C., He, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65547-9 · Cited by 9
The Handbook of Medicinal Chemistry: Principles and Practice
(2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781837671076 · Cited by 9
The Impacts and Changes Related to the Cancer Drug Resistance Mechanism
Varshney, P., Sharma, V., Yadav, D., Kumar, Y., Singh, A., Kagithala, N. R., Sharma, P. K., Porwal, O., Fuloria, N. K., Sharma, P. K., et al. (2023) · Current Drug Metabolism · doi:10.2174/0113892002266408231207150547 · Cited by 9
Metadata
- Authors
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Wager, Travis T.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-03-18
- Volume
- 7
- Issue
- 6
- Pages
- 767-775
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2300160852
- Cited by
- 653
- References
- 13
- Citations by year
- 2026: 104 · 2025: 121 · 2024: 103 · 2023: 75 · 2022: 72 · 2021: 45 · 2020: 37 · 2019: 32 · 2018: 40 · 2017: 19 · 2016: 5
- FWCI
- 30.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- desirability function, drug candidate design, ADME properties, blood-brain barrier permeability, ClogP, topological polar surface area, drug safety, drug discovery
- MeSH terms
- Algorithms, Animals, Biological Transport, Blood-Brain Barrier, Central Nervous System, Humans, Permeability, Drug Design, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.